Table Info

Table 1.

List of potential mitochondrial biomarkers involved in liver metastases by MPM invasive cells

Gene	Full name	Change #
Slc25a5	ADP/ATP translocase 2	↓
Prdx5	Peroxiredoxin-5, mitochondrial	↓
Acadm	Medium-chain specific acyl-CoA dehydrogenase, mitochondrial	↓
Acads	Short-chain specific acyl-CoA dehydrogenase, mitochondrial	↓
Hmgcs2	Hydroxymethylglutaryl-CoA synthase, mitochondrial	↓
Idh3a	Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial	↓
Dlat	Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial	↓
Cpox	Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial	↓
Ndufa10	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial	↓
Aldh5a1	Succinate-semialdehyde dehydrogenase, mitochondrial	↓
Fis1	Mitochondrial fission 1 protein	↓
Sardh	Sarcosine dehydrogenase, mitochondrial	↓
Nln	Neurolysin, mitochondrial	↓
Acadl	Long-chain specific acyl-CoA dehydrogenase, mitochondrial	↑
Aco2	Aconitate hydratase, mitochondrial	↑
Hadha	Trifunctional enzyme subunit alpha, mitochondrial	↑
Grpel1	GrpE protein homolog 1, mitochondrial	↑
Micu1	Calcium uptake protein 1, mitochondrial	↑
Uqcrq	Cytochrome b-c1 complex subunit 8	↑
Vdac2	Voltage-dependent anion-selective channel protein 2	↑
Ogdh	2-oxoglutarate dehydrogenase, mitochondrial	↑
Phb	Prohibitin	↑
Mgst1*	Microsomal glutathione S-transferase 1	↑
Decr1*	2,4-dienoyl-CoA reductase 1	↓
Prdx3*	Thioredoxin-dependent peroxide reductase, mitochondrial	↓

* Proteins not strictly located in the mitochondria (according to https://www.proteinatlas.org/). Gene names are given for Rattus norvegicus (according to https://www.uniprot.org/). #: significant changes (P < 0.05) in G2 vs. G1, and G3 vs. G2. ↑: increase; ↓: decrease

Note. Adapted from “Curcumin treatment identifies therapeutic targets within biomarkers of liver colonization by highly invasive mesothelioma cells—potential links with sarcomas,” by Pouliquen DL, Boissard A, Henry C, Blandin S, Richomme P, Coqueret O, et al. Cancers (Basel). 2020;12:3384 (https://www.mdpi.com/2072-6694/12/11/3384). CC BY.

Declarations

Author contributions

DLP: Writing—original draft, Writing—review & editing.

Conflicts of interest

The author declares that he has no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publish

Not applicable.

Availability of data and materials

Not applicable.

Funding

This review was prepared with the support of the University of Angers, including the Mir program “Mobilité Internationale pour la Recherche” between the Universities of Angers (France) and Turin (Italy) in 2020–2021 and 2021–2022. The funder (University of Angers) had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Mielgo A, Schmid MC. Liver tropism in cancer: the hepatic metastatic niche. Cold Spring Harb Perspect Med. 2020;10:a037259. [DOI] [PubMed] [PMC]

Rusciano D, Lorenzoni P, Burger M. Murine models of liver metastasis. Invasion Metastasis. 1994;14:349–61. [PubMed]

Narkhede AA, Shevde LA, Rao SS. Biomimetic strategies to recapitulate organ specific microenvironments for studying breast cancer metastasis. Int J Cancer. 2017;141:1091–109. [DOI] [PubMed]

Asawa S, Nüesch M, Gvozdenovic A, Aceto N. Circulating tumour cells in gastrointestinal cancers: food for thought? Br J Cancer. 2023;128:1981–90. [DOI] [PubMed] [PMC]

Grant CR, Liberal R. Liver immunology: How to reconcile tolerance with autoimmunity. Clin Res Hepatol Gastroenterol. 2017;41:6–16. [DOI] [PubMed]

Marvin DL, Heijboer R, Ten Dijke P, Ritsma L. TGF-β signaling in liver metastasis. Clin Transl Med. 2020;10:e160. [DOI] [PubMed] [PMC]

Tsilimigras DI, Brodt P, Clavien PA, Muschel RJ, D’Angelica MI, Endo I, et al. Liver metastases. Nat Rev Dis Primers. 2021;7:27. [DOI] [PubMed]

Wang Z, Wu X, Chen HN, Wang K. Amino acid metabolic reprogramming in tumor metastatic colonization. Front Oncol. 2023;13:1123192. [DOI] [PubMed] [PMC]

Schild T, Low V, Blenis J, Gomes AP. Unique metabolic adaptations dictate distal organ-specific metastatic colonization. Cancer Cell. 2018;33:347–54. [DOI] [PubMed] [PMC]

10.

Spennati G, Horowitz LF, McGarry DJ, Rudzka DA, Armstrong G, Olson MF, et al. Organotypic platform for studying cancer cell metastasis. Exp Cell Res. 2021;401:112527. [DOI] [PubMed] [PMC]

11.

Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer. 2021;21:541–57. [DOI] [PubMed]

12.

Urabe F, Patil K, Ramm GA, Ochiya T, Soekmadji C. Extracellular vesicles in the development of organ-specific metastasis. J Extracell Vesicles. 2021;10:e12125. [DOI] [PubMed] [PMC]

13.

Brodt P. Role of the microenvironment in liver metastasis: from pre- to prometastatic niches. Clin Cancer Res. 2016;22:5971–82. [DOI] [PubMed]

14.

Ormseth B, Onuma A, Zhang H, Tsung A. The hepatic pre-metastatic niche. Cancers (Basel). 2022;14:3731. [DOI] [PubMed] [PMC]

15.

Boulter L, Bullock E, Mabruk Z, Brunton VG. The fibrotic and immune microenvironments as targetable drivers of metastasis. Br J Cancer. 2021;124:27–36. [DOI] [PubMed] [PMC]

16.

Lee J, Beatty GL. Serum amyloid A proteins and their impact on metastasis and immune biology in cancer. Cancers (Basel). 2021;13:3179. [DOI] [PubMed] [PMC]

17.

Stathearn LS, Stepanov AI, Font-Burgada J. Inflammation in primary and metastatic liver tumorigenesis-under the influence of alcohol and high-fat diets. Nutrients. 2020;12:933. [DOI] [PubMed] [PMC]

18.

Lee JW, Stone ML, Porrett PM, Thomas SK, Komar CA, Li JH, et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature. 2019;567:249–52. [DOI] [PubMed] [PMC]

19.

Li X, Wang Z, Jiao C, Zhang Y, Xia N, Yu W, et al. Hepatocyte SGK1 activated by hepatic ischemia-reperfusion promotes the recurrence of liver metastasis via IL-6/STAT3. J Transl Med. 2023;21:121. [DOI] [PubMed] [PMC]

20.

Delladetsima I, Sakellariou S, Govaere O, Poulaki E, Felekouras E, Tiniakos D. Hepatic progenitor cells in metastatic liver carcinomas. Histopathology. 2018;72:1060–5. [DOI] [PubMed]

21.

Zvibel I, Brill S, Halpern Z, Papa M. Hepatocyte extracellular matrix modulates expression of growth factors and growth factor receptors in human colon cancer cells. Exp Cell Res. 1998;245:123–31. [DOI] [PubMed]

22.

Zvibel I, Wagner A, Pasmanik-Chor M, Varol C, Oron-Karni V, Santo EM, et al. Transcriptional profiling identifies genes induced by hepatocyte-derived extracellular matrix in metastatic human colorectal cancer cell lines. Clin Exp Metastasis. 2013;30:189–200. [DOI] [PubMed]

23.

Shimizu S, Yamada N, Sawada T, Ikeda K, Nakatani K, Seki S, et al. Ultrastructure of early phase hepatic metastasis of human colon carcinoma cells with special reference to desmosomal junctions with hepatocytes. Pathol Int. 2000;50:953–9. [DOI] [PubMed]

24.

Cox TR, Bird D, Baker AM, Barker HE, Ho MWY, Lang G, et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res. 2013;73:1721–32. [DOI] [PubMed] [PMC]

25.

Liu Y, Wang G, Liang Z, Mei Z, Wu T, Cui A, et al. Lysyl oxidase: a colorectal cancer biomarker of lung and hepatic metastasis. Thorac Cancer. 2018;9:785–93. [DOI] [PubMed] [PMC]

26.

Paolillo M, Schinelli S. Extracellular matrix alterations in metastatic processes. Int J Mol Sci. 2019;20:4947. [DOI] [PubMed] [PMC]

27.

Casal JI, Bartolomé RA. RGD cadherins and α2β1 integrin in cancer metastasis: a dangerous liaison. Biochim Biophys Acta Rev Cancer. 2018;1869:321–32. [DOI] [PubMed]

28.

Lim AR, Ghajar CM. Thorny ground, rocky soil: tissue-specific mechanisms of tumor dormancy and relapse. Semin Cancer Biol. 2022;78:104–23. [DOI] [PubMed] [PMC]

29.

Blazquez R, Sparrer D, Wendl C, Evert M, Riemenschneider MJ, Krahn MP, et al. The macro-metastasis/organ parenchyma interface (MMPI) - a hitherto unnoticed area. Semin Cancer Biol. 2020;60:324–33. [DOI] [PubMed]

30.

Paschos KA, Majeed AW, Bird NC. Natural history of hepatic metastases from colorectal cancer - pathobiological pathways with clinical significance. World J Gastroenterol. 2014;20:3719–37. [DOI] [PubMed] [PMC]

31.

Tepelenis K, Pappas-Gogos G, Ntellas P, Tsimogiannis K, Dadouli K, Mauri D, et al. The role of preoperative chemotherapy in the management of synchronous resectable colorectal liver metastases: a meta-analysis. Curr Oncol. 2023;30:4499–511. [DOI] [PubMed] [PMC]

32.

de Cuba EMV, Kwakman R, van Egmond M, Bosch LJW, Bonjer HJ, Meijer GA, et al. Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer: future possibilities for personalized treatment by use of biomarkers. Virchows Arch. 2012;461:231–43. [DOI] [PubMed]

33.

Yang L, Li T, Shi H, Zhou Z, Huang Z, Lei X. The cellular and molecular components involved in pre-metastatic niche formation in colorectal cancer liver metastasis. Expert Rev Gastroenterol Hepatol. 2021;15:389–99. [DOI] [PubMed]

34.

Guo S, Li J, Huang Z, Yue T, Zhu J, Wang X, et al. The CBS-H₂S axis promotes liver metastasis of colon cancer by upregulating VEGF through AP-1 activation. Br J Cancer. 2022;126:1055–66. [DOI] [PubMed] [PMC]

35.

Zhao S, Mi Y, Zheng B, Wei P, Gu Y, Zhang Z, et al. Highly-metastatic colorectal cancer cell released miR-181a-5p-rich extracellular vesicles promote liver metastasis by activating hepatic stellate cells and remodelling the tumour microenvironment. J Extracell Vesicles. 2022;11:e12186. [DOI] [PubMed] [PMC]

36.

Jiang K, Chen H, Fang Y, Chen L, Zhong C, Bu T, et al. Exosomal ANGPTL1 attenuates colorectal cancer liver metastasis by regulating Kupffer cell secretion pattern and impeding MMP9 induced vascular leakiness. J Exp Clin Cancer Res. 2021;40:21. [DOI] [PubMed] [PMC]

37.

Rao VS, Gu Q, Tzschentke S, Lin K, Ganig N, Thepkaysone ML, et al. Extravesicular TIMP-1 is a non-invasive independent prognostic marker and potential therapeutic target in colorectal liver metastases. Oncogene. 2022;41:1809–20. [DOI] [PubMed] [PMC]

38.

Lafitte M, Sirvent A, Roche S. Collagen kinase receptors as potential therapeutic targets in metastatic colon cancer. Front Oncol. 2020;10:125. [DOI] [PubMed] [PMC]

39.

Dmello RS, To SQ, Chand AL. Therapeutic targeting of the tumour microenvironment in metastatic colorectal cancer. Int J Mol Sci. 2021;22:2067. [DOI] [PubMed] [PMC]

40.

González-González M, Gutiérrez ML, Sayagués JM, Muñoz-Bellvís L, Orfao A. Genomic profiling of sporadic liver metastatic colorectal cancer. Semin Cancer Biol. 2021;71:98–108. [DOI] [PubMed]

41.

Teng S, Li YE, Yang M, Qi R, Huang Y, Wang Q, et al. Tissue-specific transcription reprogramming promotes liver metastasis of colorectal cancer. Cell Res. 2020;30:34–49. [DOI] [PubMed] [PMC]

42.

Zeng X, Zhou J, Xiong Z, Sun H, Yang W, Mok MTS, et al. Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis. Cell Mol Immunol. 2021;18:1005–15. [DOI] [PubMed] [PMC]

43.

Bu P, Chen KY, Xiang K, Johnson C, Crown SB, Rakhilin N, et al. Aldolase B mediated fructose metabolism drives metabolic reprograming of colon cancer liver metastasis. Cell Metab. 2018;27:1249–62.e4. [DOI] [PubMed] [PMC]

44.

Parkinson EK, Adamski J, Zahn G, Gaumann A, Flores-Borja F, Ziegler C, et al. Extracellular citrate and metabolic adaptations of cancer cells. Cancer Metastasis Rev. 2021;40:1073–91. [DOI] [PubMed] [PMC]

45.

Nguyen A, Loo JM, Mital R, Weinberg EM, Man FY, Zeng Z, et al. PKLR promotes colorectal cancer liver colonization through induction of glutathione synthesis. J Clin Invest. 2016;126:68–94. [DOI] [PubMed] [PMC]

46.

Tian GA, Xu CJ, Zhou KX, Zhang ZG, Gu JR, Zhang XL, et al. MPC1 deficiency promotes CRC liver metastasis via facilitating nuclear translocation of β-catenin. J Immunol Res. 2020;2020:8340329. [DOI] [PubMed] [PMC]

47.

Dai W, Xiang W, Han L, Yuan Z, Wang R, Ma Y, et al. PTPRO represses colorectal cancer tumorigenesis and progression by reprogramming fatty acid metabolism. Cancer Commun (Lond). 2022;42:848–67. [DOI] [PubMed] [PMC]

48.

Guerra B, Recio C, Aranda-Tavío H, Guerra-Rodríguez M, García-Castellano JM, Fernández-Pérez L. The mevalonate pathway, a metabolic target in cancer therapy. Front Oncol. 2021;11:626971. [DOI] [PubMed] [PMC]

49.

Zhang C, Wang XY, Zhang P, He TC, Han JH, Zhang R, et al. Cancer-derived exosomal HSPC111 promotes colorectal cancer liver metastasis by reprogramming lipid metabolism in cancer-associated fibroblasts. Cell Death Dis. 2022;13:57. [DOI] [PubMed] [PMC]

50.

Paschos KA, Canovas D, Bird NC. The engagement of selectins and their ligands in colorectal cancer liver metastases. J Cell Mol Med. 2010;14:165–74. [DOI] [PubMed] [PMC]

51.

Wu Y, Yang S, Ma J, Chen Z, Song G, Rao D, et al. Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level. Cancer Discov. 2022;12:134–53. [DOI] [PubMed]

52.

Zhang J, Espinoza LA, Kinders RJ, Lawrence SM, Pfister TD, Zhou M, et al. NANOG modulates stemness in human colorectal cancer. Oncogene. 2013;32:4397–405. [DOI] [PubMed] [PMC]

53.

Gonzalez-Villarreal CA, Quiroz-Reyes AG, Islas JF, Garza-Treviño EN. Colorectal cancer stem cells in the progression to liver metastasis. Front Oncol. 2020;10:1511. [DOI] [PubMed] [PMC]

54.

Shi H, Li J, Fu D. Process of hepatic metastasis from pancreatic cancer: biology with clinical significance. J Cancer Res Clin Oncol. 2016;142:1137–61. [DOI] [PubMed]

55.

Le Large TYS, Bijlsma MF, Kazemier G, van Laarhoven HWM, Giovannetti E, Jimenez CR. Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. Semin Cancer Biol. 2017;44:153–69. [DOI] [PubMed]

56.

Barbolina MV. Molecular mechanisms regulating organ-specific metastases in epithelial ovarian carcinoma. Cancers (Basel). 2018;10:444. [DOI] [PubMed] [PMC]

57.

Lewandowski RJ, Toskich BB, Brown DB, El-Haddad G, Padia SA. Role of radioembolization in metastatic neuroendocrine tumors. Cardiovasc Intervent Radiol. 2022;45:1590–8. [DOI] [PubMed]

58.

Ma B, Wells A, Wei L, Zheng J. Prostate cancer liver metastasis: dormancy and resistance to therapy. Semin Cancer Biol. 2021;71:2–9. [DOI] [PubMed]

59.

Gruszka AM, Valli D, Restelli C, Alcalay M. Adhesion deregulation in acute myeloid leukaemia. Cells. 2019;8:66. [DOI] [PubMed] [PMC]

60.

Pouliquen DL, Boissard A, Henry C, Blandin S, Richomme P, Coqueret O, et al. Curcumin treatment identifies therapeutic targets within biomarkers of liver colonization by highly invasive mesothelioma cells—potential links with sarcomas. Cancers (Basel). 2020;12:3384. [DOI] [PubMed] [PMC]

61.

Raggi C, Taddei ML, Rae C, Braconi C, Marra F. Metabolic reprogramming in cholangiocarcinoma. J Hepatol. 2022;77:849–64. [DOI] [PubMed]

62.

Ma APY, Yeung CLS, Tey SK, Mao X, Wong SWK, Ng TH, et al. Suppression of ACADM-mediated fatty acid oxidation promotes hepatocellular carcinoma via aberrant CAV1/SREBP1 signaling. Cancer Res. 2021;81:3679–92. [DOI] [PubMed]

63.

Mitsuyoshi H, Yasui K, Harano Y, Endo M, Tsuji K, Minami M, et al. Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol Res. 2009;39:366–73. [DOI] [PubMed]

64.

Sotelo-González AM, Reynoso-Camacho R, Hernández-Calvillo AK, Castañón-Servín AP, García-Gutiérrez DG, Gómez-Velázquez HDJ, et al. Strawberry, blueberry, and strawberry-blueberry blend beverages prevent hepatic steatosis in obese rats by modulating key genes involved in lipid metabolism. Int J Environ Res Public Health. 2023;20:4418. [DOI] [PubMed] [PMC]

65.

Chen D, Feng X, Lv Z, Xu X, Lu Y, Wu W, et al. ACADS acts as a potential methylation biomarker associated with the proliferation and metastasis of hepatocellular carcinomas. Aging (Albany NY). 2019;11:8825–44. [DOI] [PubMed] [PMC]

66.

Pouliquen DL, Ortone G, Rumiano L, Boissard A, Henry C, Blandin S, et al. Long-chain acyl coenzyme a dehydrogenase, a key player in metabolic rewiring/invasiveness in experimental tumors and human mesothelioma cell lines. Cancers (Basel). 2023;15:3044. [DOI] [PubMed] [PMC]

67.

Cai J, Chen T, Jiang Z, Yan J, Ye Z, Ruan Y, et al. Bulk and single-cell transcriptome profiling reveal extracellular matrix mechanical regulation of lipid metabolism reprograming through YAP/TEAD4/ACADL axis in hepatocellular carcinoma. Int J Biol Sci. 2023;19:2114–31. [DOI] [PubMed] [PMC]

68.

Di Carlo C, Sousa BC, Manfredi M, Brandi J, Dalla Pozza E, Marengo E, et al. Integrated lipidomics and proteomics reveal cardiolipin alterations, upregulation of HADHA and long chain fatty acids in pancreatic cancer stem cells. Sci Rep. 2021;11:13297. [DOI] [PubMed] [PMC]

69.

Asif S, Kim RY, Fatica T, Sim J, Zhao X, Oh Y, et al. Hmgcs2-mediated ketogenesis modulates high-fat diet-induced hepatosteatosis. Mol Metab. 2022;61:101494. [DOI] [PubMed] [PMC]

70.

Zhou Y, Gu T, Hu S, Luo Z, Huang L, Yu C, et al. Liver HMGCS2 is critical in the maintenance of liver lipid homeostasis during fasting. Genes Dis. 2023;10:694–7. [DOI] [PubMed] [PMC]

71.

Goetzman ES. Chapter 10 - Modeling disorders of fatty acid metabolism in the mouse. In: Chang KT, Min CK, editors. Progress in molecular biology and translational science. Academic Press; 2011. pp. 389–417. [DOI] [PubMed]

72.

Blomme A, Ford CA, Mui E, Patel R, Ntala C, Jamieson LE, et al. 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer. Nat Commun. 2020;11:2508. [DOI] [PubMed] [PMC]

73.

Módis K, Ramanujam VMS, Govar AA, Lopez E, Anderson KE, Wang R, et al. Cystathionine-γ-lyase (CSE) deficiency increases erythropoiesis and promotes mitochondrial electron transport via the upregulation of coproporphyrinogen III oxidase and consequent stimulation of heme biosynthesis. Biochem Pharmacol. 2019;169:113604. [DOI] [PubMed] [PMC]

74.

Xie J, Zhao Y, Dong N, Tian X, Feng J, Liu P, et al. Proteomics and transcriptomics jointly identify the key role of oxidative phosphorylation in fluoride-induced myocardial mitochondrial dysfunction in rats. Ecotoxicol Environ Saf. 2021;218:112271. [DOI] [PubMed]

75.

Ding N, Wang K, Jiang H, Yang M, Zhang L, Fan X, et al. AGK regulates the progression to NASH by affecting mitochondria complex I function. Theranostics. 2022;12:3237–50. [DOI] [PubMed] [PMC]

76.

Zeng F, Shi M, Xiao H, Chi X. WGCNA-based identification of hub genes and key pathways involved in nonalcoholic fatty liver disease. BioMed Res Int. 2021;2021:5633211. [DOI] [PubMed] [PMC]

77.

Tian R, Xu S, Chai S, Yin D, Zakon H, Yang G. Stronger selective constraint on downstream genes in the oxidative phosphorylation pathway of cetaceans. J Evol Biol. 2018;31:217–28. [DOI] [PubMed]

78.

Dauch P, Masuo Y, Vincent JP, Checler F. Endopeptidase 24-16 in murines: tissue distribution, cerebral regionalization, and ontogeny. J Neurochem. 1992;59:1862–7. [DOI] [PubMed]

79.

Mirali S, Botham A, Voisin V, Xu C, St-Germain J, Sharon D, et al. The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability. Sci Transl Med. 2020;12:eaaz8264. [DOI] [PubMed]

80.

Mirali S, Schimmer AD. The role of mitochondrial proteases in leukemic cells and leukemic stem cells. Stem Cells Transl Med. 2020;9:1481–7. [DOI] [PubMed] [PMC]

81.

Clémençon B, Babot M, Trézéguet V. The mitochondrial ADP/ATP carrier (SLC25 family): pathological implications of its dysfunction. Mol Aspects Med. 2013;34:485–93. [DOI] [PubMed]

82.

Chen YJ, Hong WF, Liu ML, Guo X, Yu YY, Cui YH, et al. An integrated bioinformatic investigation of mitochondrial solute carrier family 25 (SLC25) in colon cancer followed by preliminary validation of member 5 (SLC25A5) in tumorigenesis. Cell Death Dis. 2022;13:237. [DOI] [PubMed] [PMC]

83.

Martel C, Wang Z, Brenner C. VDAC phosphorylation, a lipid sensor influencing the cell fate. Mitochondrion. 2014;19:69–77. [DOI] [PubMed]

84.

Maurya SR, Mahalakshmi R. VDAC-2: mitochondrial outer membrane regulator masquerading as a channel? FEBS J. 2016;283:1831–6. [DOI] [PubMed] [PMC]

85.

Naghdi S, Hajnóczky G. VDAC2-specific cellular functions and the underlying structure. Biochim Biophys Acta. 2016;1863:2503–14. [DOI] [PubMed] [PMC]

86.

Yang X, Tang S, Li D, Li B, Xiao X. ROS-mediated oligomerization of VDAC2 is associated with quinocetone-induced apoptotic cell death. Toxicol In Vitro. 2018;47:195–206. [DOI] [PubMed]

87.

Yuan Z, Dewson G, Czabotar PE, Birkinshaw RW. VDAC2 and the BCL-2 family of proteins. Biochem Soc Trans. 2021;49:2787–95. [DOI] [PubMed] [PMC]

88.

Neupane N, Rajendran J, Kvist J, Harjuhaahto S, Hu B, Kinnunen V, et al. Inter-organellar and systemic responses to impaired mitochondrial matrix protein import in skeletal muscle. Commun Biol. 2022;5:1060. [DOI] [PubMed] [PMC]

89.

López-Lluch G. Mitochondrial activity and dynamics changes regarding metabolism in ageing and obesity. Mech Ageing Dev. 2017;162:108–21. [DOI] [PubMed]

90.

Ihenacho UK, Meacham KA, Harwig MC, Widlansky ME, Hill RB. Mitochondrial fission protein 1: emerging roles in organellar form and function in health and disease. Front Endocrinol (Lausanne). 2021;12:660095. [DOI] [PubMed] [PMC]

91.

Liou YH, Personnaz J, Jacobi D, Knudsen NH, Chalom MM, Starost KA, et al. Hepatic Fis1 regulates mitochondrial integrated stress response and improves metabolic homeostasis. JCI Insight. 2022;7:e150041. [DOI] [PubMed] [PMC]

92.

Vidyadharan VA, Blesson CS, Tanchico D, Betancourt A, Smith C, Yallampalli C. Low protein programming causes increased mitochondrial fusion and decreased oxygen consumption in the hepatocytes of female rats. Nutrients. 2023;15:1568. [DOI] [PubMed] [PMC]

93.

Yanran W, Jung S, Ko KS. Saturated fatty acid-induced impairment of hepatic lipid metabolism is worsened by prohibitin 1 deficiency in hepatocytes. J Med Food. 2022;25:845–52. [DOI] [PubMed]

94.

Roh MS, Ekman LG, Jeevanandam M, Brennan MF. Elevated energy expenditure in hepatocytes from tumor-bearing rats. J Surg Res. 1985;38:407–15. [DOI] [PubMed]

95.

Pouliquen DL. Hepatic mitochondrial function and brain tumours. Curr Opin Clin Nutr Metab Care. 2007;10:475–9. [DOI] [PubMed]

96.

Pouliquen D, Olivier C, Debien E, Meflah K, Vallette FM, Menanteau J. Changes in liver mitochondrial plasticity induced by brain tumor. BMC Cancer. 2006;6:234. [DOI] [PubMed] [PMC]

97.

Lu X, Yang P, Zhao X, Jiang M, Hu S, Ouyang Y, et al. OGDH mediates the inhibition of SIRT5 on cell proliferation and migration of gastric cancer. Exp Cell Res. 2019;382:111483. [DOI] [PubMed]

98.

Lu K, Han DH. A review of the mechanism of succinylation in cancer. Medicine (Baltimore). 2022;101:e31493. [DOI] [PubMed] [PMC]

99.

Owen OE, Kalhan SC, Hanson RW. The key role of anaplerosis and cataplerosis for citric acid cycle function. J Biol Chem. 2002;277:30409–12. [DOI] [PubMed]

100.

Lu Q, Tian X, Wu H, Huang J, Li M, Mei Z, et al. Metabolic changes of hepatocytes in NAFLD. Front Physiol. 2021;12:710420. [DOI] [PubMed] [PMC]

101.

Desideri E, Vegliante R, Ciriolo MR. Mitochondrial dysfunctions in cancer: genetic defects and oncogenic signaling impinging on TCA cycle activity. Cancer Lett. 2015;356:217–23. [DOI] [PubMed]

102.

You X, Tian J, Zhang H, Guo Y, Yang J, Zhu C, et al. Loss of mitochondrial aconitase promotes colorectal cancer progression via SCD1-mediated lipid remodeling. Mol Metab. 2021;48:101203. [DOI] [PubMed] [PMC]

103.

Yang R, Li Y, Wang Y, Zhang J, Fan Q, Tan J, et al. NHR-80 senses the mitochondrial UPR to rewire citrate metabolism for lipid accumulation in Caenorhabditis elegans. Cell Rep. 2022;38:110206. [DOI] [PubMed]

104.

Ravasz D, Kacso G, Fodor V, Horvath K, Adam-Vizi V, Chinopoulos C. Catabolism of GABA, succinic semialdehyde or gamma-hydroxybutyrate through the GABA shunt impair mitochondrial substrate-level phosphorylation. Neurochem Int. 2017;109:41–53. [DOI] [PubMed]

105.

Ismail T, Kim Y, Lee H, Lee DS, Lee HS. Interplay between mitochondrial peroxiredoxins and ROS in cancer development and progression. Int J Mol Sci. 2019;20:4407. [DOI] [PubMed] [PMC]

106.

Wang YG, Li L, Liu CH, Hong S, Zhang MJ. Peroxiredoxin 3 is resistant to oxidation-induced apoptosis of Hep-3b cells. Clin Transl Oncol. 2014;16:561–6. [DOI] [PubMed]

107.

Shi L, Wu LL, Yang JR, Chen XF, Zhang Y, Chen ZQ, et al. Serum peroxiredoxin3 is a useful biomarker for early diagnosis and assessment of prognosis of hepatocellular carcinoma in Chinese patients. Asian Pacif J Cancer Prev. 2014;15:2979–86. [DOI] [PubMed]

108.

Feng Q, Zhao N, Xia W, Liang C, Dai G, Yang J, et al. Integrative proteomics and immunochemistry analysis of the factors in the necrosis and repair in acetaminophen-induced acute liver injury in mice. J Cell Physiol. 2019;234:6561–81. [DOI] [PubMed]

109.

Geng Y, Wang Y, Sun R, Kang X, Zhao H, Zhu M, et al. Carnosol alleviates nonalcoholic fatty liver disease by inhibiting mitochondrial dysfunction and apoptosis through targeting of PRDX3. Toxicol Appl Pharmacol. 2021;432:115758. [DOI] [PubMed]

110.

Sun R, Tian X, Li Y, Zhao Y, Wang Z, Hu Y, et al. The m6A reader YTHDF3-mediated PRDX3 translation alleviates liver fibrosis. Redox Biol. 2022;54:102378. [DOI] [PubMed] [PMC]

111.

De Simoni S, Linard D, Hermans E, Knoops B, Goemaere J. Mitochondrial peroxiredoxin-5 as potential modulator of mitochondria-ER crosstalk in MPP⁺-induced cell death. J Neurochem. 2013;125:473–85. [DOI] [PubMed]

112.

Sienko J, Gaj P, Czajkowski K, Nowis D. Peroxiredoxin-5 is a negative survival predictor in ovarian cancer. Ginekol Pol. 2019;90:1–6. [DOI] [PubMed]

113.

Wu J, Tang Q, Shen J, Yao A, Wang F, Pu L, et al. Comparative proteome profile during the early period of small-for-size liver transplantation in rats revealed the protective role of Prdx5. J Hepatol. 2010;53:73–83. [DOI] [PubMed]

114.

Kim MH, Park SJ, Kim JH, Seong JB, Kim KM, Woo HA, et al. Peroxiredoxin 5 regulates adipogenesis-attenuating oxidative stress in obese mouse models induced by a high-fat diet. Free Rad Biol Med. 2018;123:27–38. [DOI] [PubMed]

115.

Kim MH, Seong JB, Huh JW, Bae YC, Lee HS, Lee DS. Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP-activated protein kinase signaling. Redox Biol. 2020;28:101315. [DOI] [PubMed] [PMC]